Table 2. Characteristics of individuals with normoglycaemia following screening in the ADDITION-Denmark study (n = 21 451), by treatment group.
| NGT | NGT and Heart Score ≥0 to < 5 | NGT and Heart Score ≥5 to < 10 | NGT and Heart Score ≥ 10 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RC(n = 10 288) | IT(n = 6616) | IT + MI(n = 4607) | RC(n = 5042) | IT(n = 3062) | IT + MI(n = 2409) | RC(n = 2422) | IT(n = 1447) | IT + MI(n = 1163) | RC(n = 1670) | IT(n = 970) | IT + MI(n = 823) | |
| Male sex, n (%) | 5250 (51.0) | 3349 (50.6) | 2399 (52.1) | 1766 (35.0) | 996 (32.5) | 860 (35.7) | 1610 (66.5) | 966 (66.8) | 759 (65.3) | 1373 (82.2) | 818 (84.3) | 675 (82.0) |
| Mean age ( SD ) | 59.1 (6.9) | 59.0 (7.0) | 59.4 (6.9) | 56.0 (6.4) | 56.0 (6.3) | 55.8 (6.5) | 62.3 (5.1) | 62.4 (4.9) | 62.4 (4.9) | 65.1 (4.1) | 65.1 (4.2) | 65.2 (4.2) |
| Education, n (%) | ||||||||||||
| 0–10 years | 3191 (31.5) | 2135 (32.7) | 1473 (32.4) | 1483 (29.8) | 925 (30.5) | 726 (30.5) | 824 (34.5) | 491 (34.3) | 374 (32.7) | 592 (36.2) | 334 (35.1) | 307 (37.9) |
| 10–15 years | 4296 (42.4) | 2723 (41.7) | 1832 (40.3) | 2159 (43.4) | 1267 (41.8) | 969 (40.7) | 983 (41.1) | 581 (40.6) | 455 (39.8) | 672 (41.1) | 401 (42.2) | 340 (42.0) |
| >15 years | 2640 (26.1) | 1671 (25.6) | 1236 (27.2) | 1332 (26.8) | 837 (27.6) | 688 (28.9) | 582 (24.4) | 360 (25.1) | 313 (27.4) | 372 (22.7) | 216 (22.7) | 163 (20.1) |
| Previous CVD, n (%) | 470 (4.6) | 319 (4.8) | 176 (3.8) | 194 (3.8) | 109 (3.6) | 80 (3.3) | 130 (5.4) | 86 (5.9) | 47 (4.0) | 80 (4.8) | 49 (5.1) | 42 (5.1) |
| Redeemed anti hypertensive medication, n (%) | ||||||||||||
| Year 2000 | 2429 (23.6) | 1551 (23.4) | 1112 (24.1) | 1180 (23.4) | 727 (23.7) | 543 (22.5) | 606 (25.0) | 362 (25.0) | 300 (25.8) | 405 (24.3) | 223 (23.0) | 217 (26.4) |
| Year 2005 | 4161 (41.0) | 2599 (39.7) | 1827 (40.4) | 1853 (37.1) | 1107 (36.4) | 825 (34.6) | 1036 (43.5) | 602 (42.1) | 501 (43.9) | 837 (51.8) | 473 (50.3) | 422 (53.6) |
| Year 2010 | 5322 (54.9) | 3416 (54.7) | 2348 (54.4) | 2379 (48.8) | 1454 (49.3) | 1101 (47.5) | 1316 (58.8) | 791 (58.4) | 634 (58.5) | 1052 (71.8) | 592 (69.6) | 508 (71.1) |
| Redeemed glucose-lowering medication, n (%) | ||||||||||||
| Year 2000 | a | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | a | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Year 2005 | 23 (0.2) | 14 (0.2) | 9 (0.2) | 11 (0.2) | 8 (0.3) | 6 (0.3) | a | a | a | 7 (0.4) | a | a |
| Year 2010 | 160 (1.7) | 110 (1.8) | 79 (1.8) | 78 (1.6) | 49 (1.7) | 41 (1.8) | 33 (1.5) | 24 (1.8) | 20 (1.8) | 40 (2.7) | 19 (2.2) | 13 (1.8) |
| Redeemed lipid-lowering medication, n (%) | ||||||||||||
| Year 2000 | 383 (3.7) | 232 (3.5) | 142 (3.1) | 162 (3.2) | 98 (3.2) | 60 (2.5) | 111 (4.6) | 70 (4.8) | 40 (3.4) | 76 (4.6) | 44 (4.5) | 35 (4.3) |
| Year 2005 | 1582 (15.6) | 987 (15.1) | 714 (15.8) | 620 (12.4) | 376 (12.4) | 268 (11.3) | 435 (18.3) | 275 (19.2) | 200 (17.5) | 376 (23.3) | 206 (21.9) | 210 (26.7) |
| Year 2010 | 3057 (31.5) | 1913 (30.6) | 1354 (31.4) | 1250 (25.6) | 747 (25.3) | 579 (25.0) | 786 (35.1) | 481 (35.5) | 370 (34.2) | 664 (45.3) | 386 (45.4) | 334 (46.8) |
| CVD events during follow-up, n (%) | 1665 (16.22) | 983 (14.9) | 690 (15.0) | 617 (12.2) | 342 (11.2) | 248 (10.3) | 430 (17.8) | 277 (19.1) | 206 (17.7) | 460 (27.5) | 225 (23.2) | 202 (24.5) |
| Deaths during follow-up, n (%) | 825 (8.0) | 527 (8.0) | 396 (8.6) | 235 (4.7) | 155 (5.1) | 118 (4.9) | 244 (10.1) | 134 (9.3) | 114 (9.8) | 281 (16.8) | 165 (17.0) | 144 (17.5) |
| HR for CVD ( 95% CI ) | – | 0.94(0.86 to 1.03) | 0.87(0.79 to 0.96) | – | 0.92 (0.80 to 1.06) | 0.81 (0.69 to 0.94) | – | 1.10 (0.93 to 1.30) | 0.95 (0.78 to 1.17) | – | 0.84 (0.72 to 0.97) | 0.85 (0.74 to 0.99) |
| HR for all-cause mortality ( 95% CI ) | – | 1.05(0.92 to 1.19) | 0.98(0.86 to 1.12) | – | 1.12 (0.89 to 1.40) | 1.00 (0.81 to 1.23) | – | 0.94 (0.78 to 1.14) | 0.90 (0.76 to 1.07) | – | 1.05 (0.86 to 1.27) | 1.01 (0.79 to 1.28) |
CVD = cardiovascular disease. HR = hazard ratio. IT = intensive treatment. MI = motivational interviewing. NGT = normal glucose tolerance. SD = standard deviation.
aNumbers too small to report (Denmark Statistics regulations).
Some percentages may not add up to expected total due to reducing cohort size over time and a small amount of missing data for some variables